In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …